Kprn.Ns

KPRN.NS maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.29, indicating a low reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.76, suggesting it can cover short-term obligations but with limited excess cash. However, the company's cash and equivalents of INR 1.15 million are significantly lower than its long-term debt of INR 1.48 billion, resulting in a net cash negative position.

Profitability metrics show a return on equity (ROE) of 7.44% and a return on assets (ROA) of 4.57%, both below the industry median for pharmaceutical firms. The company's operating margin is 9.3%, and its net margin is 6.1%, which are in line with the sector average but suggest limited room for margin expansion. Gross profit of INR 1.92 billion supports this, but the operating income of INR 586 million indicates some pressure from operating expenses.

Geographically, KPRN.NS is concentrated in a single market, with all revenue derived from domestic operations. This lack of geographic diversification increases exposure to local regulatory and economic risks. The company does not disclose segment-level revenue, but its business is entirely focused on pharmaceuticals, with no diversification into medical research or other healthcare subsectors.

The company's growth trajectory is modest, with revenue of INR 6.3 billion in the latest period. While the operating cash flow of INR 419 million is positive, the free cash flow is negative at INR -192 million, driven by capital expenditures of INR -589 million. This suggests the company is investing in long-term infrastructure but is not generating sufficient cash to fund these investments organically.

Risk factors include a medium liquidity risk due to the current ratio and a net cash negative position. The dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. However, the company's capital expenditures and negative free cash flow may require future financing, which could introduce dilution pressure if not offset by organic cash generation.

Recent filings and transcripts indicate no major strategic shifts or regulatory challenges. The company remains focused on its core pharmaceutical business, with no disclosed plans for M&A or new therapeutic areas. The absence of recent capital raises or equity offerings supports the low dilution risk assessment.